

Curriculum Vitae, Jared Probst, M.D.

**Jared Probst, M.D.**

Cognitive Clinical Trials Research  
8901 E. Pima Center Parkway, Suite 115  
Scottsdale, AZ 85258

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Alliance Director  
Tel. (916) 939-6696  
Fax (208) 575-3169  
Email: clinicaltrials@alliancesites.com

**AFFILIATIONS:**

South Ogden Family Practice/Ogden Clinic  
5740 Crestwood Drive  
South Ogden, UT 84405

Olympus Family Medicine  
4624 Holladay Blvd E  
Salt Lake City, UT 84117

**EDUCATION:**

1996 MD  
University of Utah School of Medicine, Salt Lake City, Utah

1992 BS Sociology  
Utah State University, Logan, Utah

**LICENSURE:**

Utah - Physician - License Number: 373445-1205  
Utah - Physician CS - License Number: 373445-8905

**RESIDENCY:**

1996-1999 Family Practice  
Medical College of Wisconsin, Milwaukee, Wisconsin

**CERTIFICATION:**

American Board of Family Medicine – Certified

**PROFESSIONAL EXPERIENCE:**

*Principal Investigator*, 2020 – present  
CCT Research (Cognitive Clinical Trials Research, LLC), Utah

*Principal Investigator*, 2016 – 2020  
Accelerated Enrollment Solutions (formerly Synexus Clinical Research), Holladay, Utah

*Family Practice Physician*, 1999 – Present  
Olympus Family Medicine, Holladay, Utah

*Emergency Physician*, 1998 – 1999  
St. Nicholas Hospital, Sheboygan, Wisconsin

*Urgent Care Physician*, 1997 – 1999  
St. Mary's Clinic, Milwaukee, Wisconsin

*Volunteer Physician*, 1997 – 1999  
Isaac Cogg Homeless Clinic, Milwaukee, Wisconsin

**INVESTIGATOR EXPERIENCE:**

Type 2 Diabetes • COVID-19 Antigen Test

**CLINICAL TRIAL EXPERIENCE:**

Clinical Evaluation of the XXX COVID-19 Ag AnTigen (Ag) Assay in Symptomatic Subjects (CATSS)

A 52 Week Randomized, Double-Blind, Double-Dummy, Active And Placebo Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety Of XXX Compared To XXX Or Placebo Added To XXX In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy

A 26 Week Randomized, Double-Blind, Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy And Safety Of XXX Compared To XXX, And Placebo In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control On Dipeptidyl Peptidase 4 Inhibiter (DPP41) With Or Without Metformin

A 56 Week, Multicenter, Double-Blind, Placebo Controlled, Randomized Study To Evaluate The Efficacy And Safety Of XXX Once Weekly In Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet And Exercise